{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:6968"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:6968","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Reconstitution of CMV-specific T-cells following adoptive T-cell immunotherapy and haematopoietic stem cell transplantation","abstract":"This thesis investigated reconstitution of CMV-specific T-cells in two cohorts of HSCT patients and studied the potential role of Tumour Necrosis Factor Receptor 2 (TNFR2) in regulation of CMV-specific T-cell expansion post HSCT. The first cohort included patients of a randomized phase II trial of adoptive cellular therapy for CMV-specific CD8\\(^+\\) T-cells. Cellular therapy resulted in earlier and greater expansion of CMV-specific CD8\\(^+\\) T cells and also reconstitution of CMV-specific CD4\\(^+\\) and non-infused CMV-specific CD8\\(^+\\) T-cells. The number of infused therapeutic T-cells and circulating levels of Alemtuzumab were found to influence immunotherapy. Additionally, reconstitution of CMV-specific CD4\\(^+\\) T-cells was studied using HLA-class II tetramers. CMV-specific CD4\\(^+\\) T-cell count of >0.7x10\\(^3\\)/ml was found to protect from recurrent CMV reactivation. One third of specific CD4\\(^+\\) T-cells were perforin and granzyme-B positive indicating cytotoxic potential, whilst the majority expressed T-bet. Expression of CD57 molecule on CD4\\(^+\\) T-cells was demonstrated as a potential biomarker of immune response to CMV. Also, distinct cytokine receptor expression patterns in naïve versus memory T-cells were observed. The results showed rapid decrease in IL-6R and increase in expression of TNFR2 after T-cell differentiation from naïve to effector cells and engagement of TNFR2 led to the apoptosis of CMV-specific T-cells.","abstract_html":"This thesis investigated reconstitution of CMV-specific T-cells in two cohorts of HSCT patients and studied the potential role of Tumour Necrosis Factor Receptor 2 (TNFR2) in regulation of CMV-specific T-cell expansion post HSCT. The first cohort included patients of a randomized phase II trial of adoptive cellular therapy for CMV-specific CD8<span class=\"etd-inline-math\"><sup>+</sup></span> T-cells. Cellular therapy resulted in earlier and greater expansion of CMV-specific CD8<span class=\"etd-inline-math\"><sup>+</sup></span> T cells and also reconstitution of CMV-specific CD4<span class=\"etd-inline-math\"><sup>+</sup></span> and non-infused CMV-specific CD8<span class=\"etd-inline-math\"><sup>+</sup></span> T-cells. The number of infused therapeutic T-cells and circulating levels of Alemtuzumab were found to influence immunotherapy. Additionally, reconstitution of CMV-specific CD4<span class=\"etd-inline-math\"><sup>+</sup></span> T-cells was studied using HLA-class II tetramers. CMV-specific CD4<span class=\"etd-inline-math\"><sup>+</sup></span> T-cell count of &gt;0.7x10<span class=\"etd-inline-math\"><sup>3</sup></span>/ml was found to protect from recurrent CMV reactivation. One third of specific CD4<span class=\"etd-inline-math\"><sup>+</sup></span> T-cells were perforin and granzyme-B positive indicating cytotoxic potential, whilst the majority expressed T-bet. Expression of CD57 molecule on CD4<span class=\"etd-inline-math\"><sup>+</sup></span> T-cells was demonstrated as a potential biomarker of immune response to CMV. Also, distinct cytokine receptor expression patterns in naïve versus memory T-cells were observed. The results showed rapid decrease in IL-6R and increase in expression of TNFR2 after T-cell differentiation from naïve to effector cells and engagement of TNFR2 led to the apoptosis of CMV-specific T-cells.","abstract_has_math":true,"creators":["Raeiszadeh, Mohammad"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2016,"date_issued":"2016-12","date_published":"2016-12","updated_at":"2026-11-19T09:29:07Z","subjects":["QH301 Biology","QH426 Genetics"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/6968/5/Raeiszadeh16PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A6968","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["bloodwise"]},{"key":"dc:creator","label":"Author","values":["Raeiszadeh, Mohammad"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2016-12"]},{"key":"dc:date.issued","label":"Date","values":["2016-12"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/6968/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["QH301 Biology","QH426 Genetics"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/6968/5/Raeiszadeh16PhD.pdf","http://etheses.bham.ac.uk//id/eprint/6968/1/Decl_IS_Raeiszadeh16PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["This thesis investigated reconstitution of CMV-specific T-cells in two cohorts of HSCT patients and studied the potential role of Tumour Necrosis Factor Receptor 2 (TNFR2) in regulation of CMV-specific T-cell expansion post HSCT. The first cohort included patients of a randomized phase II trial of adoptive cellular therapy for CMV-specific CD8\\(^+\\) T-cells. Cellular therapy resulted in earlier and greater expansion of CMV-specific CD8\\(^+\\) T cells and also reconstitution of CMV-specific CD4\\(^+\\) and non-infused CMV-specific CD8\\(^+\\) T-cells. The number of infused therapeutic T-cells and circulating levels of Alemtuzumab were found to influence immunotherapy. Additionally, reconstitution of CMV-specific CD4\\(^+\\) T-cells was studied using HLA-class II tetramers. CMV-specific CD4\\(^+\\) T-cell count of >0.7x10\\(^3\\)/ml was found to protect from recurrent CMV reactivation. One third of specific CD4\\(^+\\) T-cells were perforin and granzyme-B positive indicating cytotoxic potential, whilst the majority expressed T-bet. Expression of CD57 molecule on CD4\\(^+\\) T-cells was demonstrated as a potential biomarker of immune response to CMV. Also, distinct cytokine receptor expression patterns in naïve versus memory T-cells were observed. The results showed rapid decrease in IL-6R and increase in expression of TNFR2 after T-cell differentiation from naïve to effector cells and engagement of TNFR2 led to the apoptosis of CMV-specific T-cells."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public","staffonly"]},{"key":"dc:title","label":"Title","values":["Reconstitution of CMV-specific T-cells following adoptive T-cell immunotherapy and haematopoietic stem cell transplantation"]}]}],"canonical_facts":{"dc:contributor.sponsor":["bloodwise"],"dc:creator":["Raeiszadeh, Mohammad"],"dc:date":["2016-12"],"dc:date.issued":["2016-12"],"dc:description.abstract":["This thesis investigated reconstitution of CMV-specific T-cells in two cohorts of HSCT patients and studied the potential role of Tumour Necrosis Factor Receptor 2 (TNFR2) in regulation of CMV-specific T-cell expansion post HSCT. The first cohort included patients of a randomized phase II trial of adoptive cellular therapy for CMV-specific CD8\\(^+\\) T-cells. Cellular therapy resulted in earlier and greater expansion of CMV-specific CD8\\(^+\\) T cells and also reconstitution of CMV-specific CD4\\(^+\\) and non-infused CMV-specific CD8\\(^+\\) T-cells. The number of infused therapeutic T-cells and circulating levels of Alemtuzumab were found to influence immunotherapy. Additionally, reconstitution of CMV-specific CD4\\(^+\\) T-cells was studied using HLA-class II tetramers. CMV-specific CD4\\(^+\\) T-cell count of >0.7x10\\(^3\\)/ml was found to protect from recurrent CMV reactivation. One third of specific CD4\\(^+\\) T-cells were perforin and granzyme-B positive indicating cytotoxic potential, whilst the majority expressed T-bet. Expression of CD57 molecule on CD4\\(^+\\) T-cells was demonstrated as a potential biomarker of immune response to CMV. Also, distinct cytokine receptor expression patterns in naïve versus memory T-cells were observed. The results showed rapid decrease in IL-6R and increase in expression of TNFR2 after T-cell differentiation from naïve to effector cells and engagement of TNFR2 led to the apoptosis of CMV-specific T-cells."],"dc:format":["application/pdf"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/6968/5/Raeiszadeh16PhD.pdf","http://etheses.bham.ac.uk//id/eprint/6968/1/Decl_IS_Raeiszadeh16PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/6968/"],"dc:subject":["QH301 Biology","QH426 Genetics"],"dcterms:accessrights":["public","staffonly"],"dc:title":["Reconstitution of CMV-specific T-cells following adoptive T-cell immunotherapy and haematopoietic stem cell transplantation"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:29:07Z"}